25 XP   0   0   10

Anhui Anke BioTech Group
Buy, Hold or Sell?

Let's analyse Anhui Anke BioTech Group together

PenkeI guess you are interested in Anhui Anke BioTech Group. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Anhui Anke BioTech Group. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Anhui Anke BioTech Group

I send you an email if I find something interesting about Anhui Anke BioTech Group.

Quick analysis of Anhui Anke BioTech Group (30 sec.)










What can you expect buying and holding a share of Anhui Anke BioTech Group? (30 sec.)

How much money do you get?

How much money do you get?
¥0.03
When do you have the money?
1 year
How often do you get paid?
97.5%

What is your share worth?

Current worth
¥2.35
Expected worth in 1 year
¥2.66
How sure are you?
90.0%

+ What do you gain per year?

Total Gains per Share
¥0.56
Return On Investment
5.7%

For what price can you sell your share?

Current Price per Share
¥9.85
Expected price per share
¥7.0088949677419 - ¥10.47
How sure are you?
50%

1. Valuation of Anhui Anke BioTech Group (5 min.)




Live pricePrice per Share (EOD)

¥9.85

Intrinsic Value Per Share

¥3.34 - ¥5.28

Total Value Per Share

¥5.69 - ¥7.63

2. Growth of Anhui Anke BioTech Group (5 min.)




Is Anhui Anke BioTech Group growing?

Current yearPrevious yearGrowGrow %
How rich?$542.6m$441.2m$66.1m13.0%

How much money is Anhui Anke BioTech Group making?

Current yearPrevious yearGrowGrow %
Making money$29.2m$24.2m$4.9m17.0%
Net Profit Margin29.9%30.3%--

How much money comes from the company's main activities?

3. Financial Health of Anhui Anke BioTech Group (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#100 / 1010

Most Revenue
#99 / 1010

Most Profit
#67 / 1010

Most Efficient
#50 / 1010

What can you expect buying and holding a share of Anhui Anke BioTech Group? (5 min.)

Welcome investor! Anhui Anke BioTech Group's management wants to use your money to grow the business. In return you get a share of Anhui Anke BioTech Group.

What can you expect buying and holding a share of Anhui Anke BioTech Group?

First you should know what it really means to hold a share of Anhui Anke BioTech Group. And how you can make/lose money.

Speculation

The Price per Share of Anhui Anke BioTech Group is ¥9.85. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Anhui Anke BioTech Group.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Anhui Anke BioTech Group, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥2.35. Based on the TTM, the Book Value Change Per Share is ¥0.08 per quarter. Based on the YOY, the Book Value Change Per Share is ¥0.07 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.06 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Anhui Anke BioTech Group.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps0.020.2%0.020.2%0.010.1%0.010.1%0.010.1%
Usd Book Value Change Per Share0.020.2%0.010.1%0.010.1%0.010.1%0.010.1%
Usd Dividend Per Share0.000.0%0.010.1%0.010.1%0.010.1%0.000.0%
Usd Total Gains Per Share0.020.2%0.020.2%0.020.2%0.010.1%0.010.1%
Usd Price Per Share1.41-1.42-1.32-1.79-2.43-
Price to Earnings Ratio22.22-20.81-24.92-39.99-137.38-
Price-to-Total Gains Ratio81.19-74.92-78.48-116.99-156.54-
Price to Book Ratio4.36-4.71-5.04-7.28-19.97-
Price-to-Total Gains Ratio81.19-74.92-78.48-116.99-156.54-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.3593
Number of shares735
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.01
Usd Book Value Change Per Share0.010.01
Usd Total Gains Per Share0.020.01
Gains per Quarter (735 shares)14.2410.32
Gains per Year (735 shares)56.9641.29
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1253247182331
25064104364672
375961615470113
4991282187293154
512416027590116195
6149193332108139236
7174225389126163277
8199257446144186318
9224289503162209359
10249321560180232400

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%11.01.00.091.7%18.02.00.090.0%38.02.00.095.0%56.02.00.096.6%
Book Value Change Per Share3.01.00.075.0%8.04.00.066.7%13.07.00.065.0%30.010.00.075.0%45.013.00.077.6%
Dividend per Share3.00.01.075.0%11.00.01.091.7%19.00.01.095.0%39.00.01.097.5%52.00.06.089.7%
Total Gains per Share4.00.00.0100.0%11.01.00.091.7%18.02.00.090.0%36.04.00.090.0%54.04.00.093.1%

Fundamentals of Anhui Anke BioTech Group

About Anhui Anke BioTech Group

Anhui Anke Biotechnology (Group) Co., Ltd. develops, produces, and markets pharmaceutical products in China and internationally. The company offers recombinant human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. It provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life detection, sperm staining detection, sperm acrosin detection, sperm DNA fragmentation staining, and leptin and immunohistochemical diagnostic kits. In addition, the company offers adhesive plasters, oral solutions, topical preparations, and ointments; peptide APIs; beauty care and anti-aging products; and synthetic drugs in the form of oral powders, dripping pills, and tablets and capsules. Further, it provides autosomal, sex chromosome, autosomal and sex chromosome combination, and other kits, as well as paternity testing set packages; tumor biological immunotherapy products; and DNA testing professional services. Anhui Anke Biotechnology (Group) Co., Ltd. was founded in 2000 and is based in Hefei, China.

Fundamental data was last updated by Penke on 2024-04-16 11:24:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is underpriced.

1.1. Profitability of Anhui Anke BioTech Group.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Anhui Anke BioTech Group earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Anhui Anke BioTech Group to the Biotechnology industry mean.
  • A Net Profit Margin of 22.8% means that ¥0.23 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Anhui Anke BioTech Group:

  • The MRQ is 22.8%. The company is making a huge profit. +2
  • The TTM is 29.9%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ22.8%TTM29.9%-7.1%
TTM29.9%YOY30.3%-0.4%
TTM29.9%5Y20.9%+9.0%
5Y20.9%10Y21.4%-0.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ22.8%-200.1%+222.9%
TTM29.9%-216.8%+246.7%
YOY30.3%-288.3%+318.6%
5Y20.9%-449.1%+470.0%
10Y21.4%-605.5%+626.9%
1.1.2. Return on Assets

Shows how efficient Anhui Anke BioTech Group is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Anhui Anke BioTech Group to the Biotechnology industry mean.
  • 3.9% Return on Assets means that Anhui Anke BioTech Group generated ¥0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Anhui Anke BioTech Group:

  • The MRQ is 3.9%. Using its assets, the company is less efficient in making profit.
  • The TTM is 4.7%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ3.9%TTM4.7%-0.8%
TTM4.7%YOY4.5%+0.1%
TTM4.7%5Y2.9%+1.8%
5Y2.9%10Y3.0%-0.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.9%-13.3%+17.2%
TTM4.7%-12.8%+17.5%
YOY4.5%-11.7%+16.2%
5Y2.9%-13.9%+16.8%
10Y3.0%-15.7%+18.7%
1.1.3. Return on Equity

Shows how efficient Anhui Anke BioTech Group is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Anhui Anke BioTech Group to the Biotechnology industry mean.
  • 5.2% Return on Equity means Anhui Anke BioTech Group generated ¥0.05 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Anhui Anke BioTech Group:

  • The MRQ is 5.2%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 6.1%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ5.2%TTM6.1%-0.9%
TTM6.1%YOY5.8%+0.3%
TTM6.1%5Y3.6%+2.5%
5Y3.6%10Y3.8%-0.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.2%-16.9%+22.1%
TTM6.1%-16.1%+22.2%
YOY5.8%-15.1%+20.9%
5Y3.6%-19.3%+22.9%
10Y3.8%-20.2%+24.0%

1.2. Operating Efficiency of Anhui Anke BioTech Group.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Anhui Anke BioTech Group is operating .

  • Measures how much profit Anhui Anke BioTech Group makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Anhui Anke BioTech Group to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated ¥0.00  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Anhui Anke BioTech Group:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM17.9%-17.9%
TTM17.9%YOY34.6%-16.8%
TTM17.9%5Y23.8%-6.0%
5Y23.8%10Y13.5%+10.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--296.2%+296.2%
TTM17.9%-232.5%+250.4%
YOY34.6%-298.2%+332.8%
5Y23.8%-492.1%+515.9%
10Y13.5%-632.4%+645.9%
1.2.2. Operating Ratio

Measures how efficient Anhui Anke BioTech Group is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.99 means that the operating costs are ¥0.99 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Anhui Anke BioTech Group:

  • The MRQ is 0.985. The company is less efficient in keeping operating costs low.
  • The TTM is 0.875. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.985TTM0.875+0.110
TTM0.875YOY0.864+0.011
TTM0.8755Y0.911-0.036
5Y0.91110Y0.625+0.286
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9853.231-2.246
TTM0.8753.310-2.435
YOY0.8643.890-3.026
5Y0.9115.739-4.828
10Y0.6257.876-7.251

1.3. Liquidity of Anhui Anke BioTech Group.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Anhui Anke BioTech Group is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.75 means the company has ¥2.75 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Anhui Anke BioTech Group:

  • The MRQ is 2.745. The company is able to pay all its short-term debts. +1
  • The TTM is 2.940. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.745TTM2.940-0.194
TTM2.940YOY3.316-0.376
TTM2.9405Y3.453-0.513
5Y3.45310Y1.857+1.596
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.7453.890-1.145
TTM2.9404.173-1.233
YOY3.3165.344-2.028
5Y3.4536.126-2.673
10Y1.8576.448-4.591
1.3.2. Quick Ratio

Measures if Anhui Anke BioTech Group is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Anhui Anke BioTech Group to the Biotechnology industry mean.
  • A Quick Ratio of 2.06 means the company can pay off ¥2.06 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Anhui Anke BioTech Group:

  • The MRQ is 2.061. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.088. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.061TTM2.088-0.027
TTM2.088YOY2.432-0.344
TTM2.0885Y2.214-0.126
5Y2.21410Y1.784+0.430
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0613.514-1.453
TTM2.0883.998-1.910
YOY2.4325.380-2.948
5Y2.2146.105-3.891
10Y1.7846.404-4.620

1.4. Solvency of Anhui Anke BioTech Group.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Anhui Anke BioTech Group assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Anhui Anke BioTech Group to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.21 means that Anhui Anke BioTech Group assets are financed with 20.6% credit (debt) and the remaining percentage (100% - 20.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Anhui Anke BioTech Group:

  • The MRQ is 0.206. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.195. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.206TTM0.195+0.011
TTM0.195YOY0.185+0.010
TTM0.1955Y0.173+0.022
5Y0.17310Y0.178-0.006
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2060.339-0.133
TTM0.1950.336-0.141
YOY0.1850.271-0.086
5Y0.1730.366-0.193
10Y0.1780.389-0.211
1.4.2. Debt to Equity Ratio

Measures if Anhui Anke BioTech Group is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Anhui Anke BioTech Group to the Biotechnology industry mean.
  • A Debt to Equity ratio of 27.2% means that company has ¥0.27 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Anhui Anke BioTech Group:

  • The MRQ is 0.272. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.256. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.272TTM0.256+0.017
TTM0.256YOY0.240+0.016
TTM0.2565Y0.219+0.037
5Y0.21910Y0.232-0.013
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2720.388-0.116
TTM0.2560.402-0.146
YOY0.2400.335-0.095
5Y0.2190.426-0.207
10Y0.2320.461-0.229

2. Market Valuation of Anhui Anke BioTech Group

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Anhui Anke BioTech Group generates.

  • Above 15 is considered overpriced but always compare Anhui Anke BioTech Group to the Biotechnology industry mean.
  • A PE ratio of 22.22 means the investor is paying ¥22.22 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Anhui Anke BioTech Group:

  • The EOD is 21.415. Based on the earnings, the company is fair priced.
  • The MRQ is 22.220. Based on the earnings, the company is fair priced.
  • The TTM is 20.808. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD21.415MRQ22.220-0.804
MRQ22.220TTM20.808+1.412
TTM20.808YOY24.923-4.115
TTM20.8085Y39.989-19.181
5Y39.98910Y137.381-97.392
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD21.415-2.264+23.679
MRQ22.220-2.629+24.849
TTM20.808-2.680+23.488
YOY24.923-4.145+29.068
5Y39.989-6.257+46.246
10Y137.381-6.254+143.635
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Anhui Anke BioTech Group:

  • The EOD is 15.035. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 15.599. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 25.729. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD15.035MRQ15.599-0.565
MRQ15.599TTM25.729-10.130
TTM25.729YOY-43.336+69.065
TTM25.7295Y100.909-75.180
5Y100.90910Y-25.235+126.144
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD15.035-2.973+18.008
MRQ15.599-3.333+18.932
TTM25.729-3.553+29.282
YOY-43.336-5.605-37.731
5Y100.909-8.376+109.285
10Y-25.235-8.865-16.370
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Anhui Anke BioTech Group is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.36 means the investor is paying ¥4.36 for each ¥1 in book value.

Let's take a look of the Price to Book Ratio trends of Anhui Anke BioTech Group:

  • The EOD is 4.200. Based on the equity, the company is fair priced.
  • The MRQ is 4.358. Based on the equity, the company is fair priced.
  • The TTM is 4.711. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD4.200MRQ4.358-0.158
MRQ4.358TTM4.711-0.353
TTM4.711YOY5.041-0.330
TTM4.7115Y7.277-2.566
5Y7.27710Y19.970-12.693
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.2001.896+2.304
MRQ4.3582.115+2.243
TTM4.7112.093+2.618
YOY5.0412.884+2.157
5Y7.2773.542+3.735
10Y19.9703.916+16.054
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Anhui Anke BioTech Group compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.1240.079+57%0.074+68%0.057+117%0.049+155%
Book Value Per Share--2.3452.193+7%1.907+23%1.839+28%1.305+80%
Current Ratio--2.7452.940-7%3.316-17%3.453-20%1.857+48%
Debt To Asset Ratio--0.2060.195+6%0.185+11%0.173+19%0.178+15%
Debt To Equity Ratio--0.2720.256+6%0.240+13%0.219+25%0.232+18%
Dividend Per Share--0.0010.061-98%0.049-97%0.044-97%0.034-96%
Eps--0.1150.126-9%0.105+10%0.067+72%0.048+139%
Free Cash Flow Per Share--0.1640.113+45%0.033+389%0.056+192%0.040+307%
Free Cash Flow To Equity Per Share--0.1640.051+220%0.011+1437%0.040+311%0.039+316%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--5.282--------
Intrinsic Value_10Y_min--3.342--------
Intrinsic Value_1Y_max--0.322--------
Intrinsic Value_1Y_min--0.192--------
Intrinsic Value_3Y_max--1.126--------
Intrinsic Value_3Y_min--0.704--------
Intrinsic Value_5Y_max--2.120--------
Intrinsic Value_5Y_min--1.351--------
Market Cap16516775027.200-4%17137202109.44017279732655.360-1%16068223015.040+7%21757723810.476-21%29539472410.220-42%
Net Profit Margin--0.2280.299-24%0.303-25%0.209+9%0.214+7%
Operating Margin---0.179-100%0.346-100%0.238-100%0.135-100%
Operating Ratio--0.9850.875+13%0.864+14%0.911+8%0.625+58%
Pb Ratio4.200-4%4.3584.711-7%5.041-14%7.277-40%19.970-78%
Pe Ratio21.415-4%22.22020.808+7%24.923-11%39.989-44%137.381-84%
Price Per Share9.850-4%10.22010.305-1%9.583+7%12.976-21%17.616-42%
Price To Free Cash Flow Ratio15.035-4%15.59925.729-39%-43.336+378%100.909-85%-25.235+262%
Price To Total Gains Ratio78.250-4%81.19074.919+8%78.475+3%116.993-31%156.540-48%
Quick Ratio--2.0612.088-1%2.432-15%2.214-7%1.784+16%
Return On Assets--0.0390.047-16%0.045-14%0.029+36%0.030+30%
Return On Equity--0.0520.061-15%0.058-12%0.036+43%0.038+36%
Total Gains Per Share--0.1260.140-10%0.123+2%0.102+24%0.083+51%
Usd Book Value--542661803.069507403138.020+7%441272263.431+23%425462028.146+28%301980733.138+80%
Usd Book Value Change Per Share--0.0170.011+57%0.010+68%0.008+117%0.007+155%
Usd Book Value Per Share--0.3240.303+7%0.263+23%0.254+28%0.180+80%
Usd Dividend Per Share--0.0000.008-98%0.007-97%0.006-97%0.005-96%
Usd Eps--0.0160.017-9%0.014+10%0.009+72%0.007+139%
Usd Free Cash Flow--37901137.14926138418.122+45%7750008.052+389%12962605.455+192%9090377.610+317%
Usd Free Cash Flow Per Share--0.0230.016+45%0.005+389%0.008+192%0.006+307%
Usd Free Cash Flow To Equity Per Share--0.0230.007+220%0.001+1437%0.006+311%0.005+316%
Usd Market Cap2279314953.754-4%2364933891.1032384603106.440-1%2217414776.076+7%3002565885.846-21%4076447192.610-42%
Usd Price Per Share1.359-4%1.4101.422-1%1.322+7%1.791-21%2.431-42%
Usd Profit--26608445.58129229415.207-9%24264660.057+10%15460165.257+72%11125997.772+139%
Usd Revenue--116522784.45098868446.068+18%80421664.092+45%74378735.461+57%53008293.271+120%
Usd Total Gains Per Share--0.0170.019-10%0.017+2%0.014+24%0.011+51%
 EOD+4 -4MRQTTM+15 -20YOY+22 -135Y+23 -1210Y+24 -11

3.2. Fundamental Score

Let's check the fundamental score of Anhui Anke BioTech Group based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1521.415
Price to Book Ratio (EOD)Between0-14.200
Net Profit Margin (MRQ)Greater than00.228
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.061
Current Ratio (MRQ)Greater than12.745
Debt to Asset Ratio (MRQ)Less than10.206
Debt to Equity Ratio (MRQ)Less than10.272
Return on Equity (MRQ)Greater than0.150.052
Return on Assets (MRQ)Greater than0.050.039
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Anhui Anke BioTech Group based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.750
Ma 20Greater thanMa 509.727
Ma 50Greater thanMa 1009.777
Ma 100Greater thanMa 2009.800
OpenGreater thanClose9.540
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Tax Provision  37230,64131,013-38130,63210,87841,510-83,325-41,814



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in CNY. All numbers in thousands.

Summary
Total Assets4,950,760
Total Liabilities1,018,429
Total Stockholder Equity3,737,400
 As reported
Total Liabilities 1,018,429
Total Stockholder Equity+ 3,737,400
Total Assets = 4,950,760

Assets

Total Assets4,950,760
Total Current Assets2,325,483
Long-term Assets2,625,277
Total Current Assets
Cash And Cash Equivalents 260,227
Short-term Investments 1,195,572
Net Receivables 550,229
Inventory 235,215
Other Current Assets 2,350
Total Current Assets  (as reported)2,325,483
Total Current Assets  (calculated)2,243,593
+/- 81,891
Long-term Assets
Property Plant Equipment 1,433,549
Goodwill 66,557
Intangible Assets 666,314
Long-term Assets Other 8,986
Long-term Assets  (as reported)2,625,277
Long-term Assets  (calculated)2,175,405
+/- 449,872

Liabilities & Shareholders' Equity

Total Current Liabilities847,081
Long-term Liabilities171,348
Total Stockholder Equity3,737,400
Total Current Liabilities
Accounts payable 211,704
Other Current Liabilities 2,316
Total Current Liabilities  (as reported)847,081
Total Current Liabilities  (calculated)214,020
+/- 633,061
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt47,817
Long-term Liabilities  (as reported)171,348
Long-term Liabilities  (calculated)47,817
+/- 123,530
Total Stockholder Equity
Retained Earnings 1,397,770
Total Stockholder Equity (as reported)3,737,400
Total Stockholder Equity (calculated)1,397,770
+/- 2,339,630
Other
Capital Stock1,676,827
Common Stock Shares Outstanding 1,676,827
Net Invested Capital 3,737,400
Net Working Capital 1,478,403
Property Plant and Equipment Gross 1,433,549



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302008-12-312007-12-312006-12-31
> Total Assets 
225,721
236,553
222,962
217,136
552,514
542,355
552,436
574,444
579,118
589,550
589,026
572,152
587,953
603,652
611,320
583,693
620,518
652,934
670,052
680,611
713,536
749,811
758,750
784,633
822,230
915,576
891,385
908,740
959,262
1,401,293
1,438,206
1,849,471
1,870,562
1,965,244
1,957,402
1,959,837
2,088,788
2,254,143
2,349,777
2,327,666
2,412,526
2,526,966
3,281,991
3,182,852
3,246,178
3,226,206
3,266,695
3,197,213
3,340,793
3,504,879
3,687,412
3,465,899
3,687,361
3,669,086
3,914,015
3,680,284
3,857,085
4,255,326
4,480,329
4,252,565
4,591,233
4,950,760
4,950,7604,591,2334,252,5654,480,3294,255,3263,857,0853,680,2843,914,0153,669,0863,687,3613,465,8993,687,4123,504,8793,340,7933,197,2133,266,6953,226,2063,246,1783,182,8523,281,9912,526,9662,412,5262,327,6662,349,7772,254,1432,088,7881,959,8371,957,4021,965,2441,870,5621,849,4711,438,2061,401,293959,262908,740891,385915,576822,230784,633758,750749,811713,536680,611670,052652,934620,518583,693611,320603,652587,953572,152589,026589,550579,118574,444552,436542,355552,514217,136222,962236,553225,721
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
688,939
679,873
756,458
1,454,541
1,313,742
1,350,725
1,474,313
1,499,130
1,385,779
1,515,160
1,641,350
1,802,797
1,558,059
1,755,457
1,921,623
2,015,562
1,743,181
1,842,564
1,910,535
2,114,109
1,854,096
2,090,508
2,325,483
2,325,4832,090,5081,854,0962,114,1091,910,5351,842,5641,743,1812,015,5621,921,6231,755,4571,558,0591,802,7971,641,3501,515,1601,385,7791,499,1301,474,3131,350,7251,313,7421,454,541756,458679,873688,939000000000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
127,940
69,672
145,936
600,043
495,231
422,234
527,260
473,529
210,320
170,931
248,066
254,464
236,926
123,175
322,563
207,858
234,791
247,422
324,587
373,617
275,606
266,242
260,227
260,227266,242275,606373,617324,587247,422234,791207,858322,563123,175236,926254,464248,066170,931210,320473,529527,260422,234495,231600,043145,93669,672127,940000000000000000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
460
0
0
0
124,990
0
177,846
240,482
426,293
523,661
646,451
722,346
529,426
821,917
805,425
982,197
665,442
755,464
842,906
952,977
738,395
978,259
1,195,572
1,195,572978,259738,395952,977842,906755,464665,442982,197805,425821,917529,426722,346646,451523,661426,293240,482177,8460124,990000460000000000000000000000000000000000000000
       Net Receivables 
44,286
42,995
55,504
53,846
64,575
61,313
64,824
70,922
80,145
82,170
87,933
86,427
100,066
114,070
116,254
115,723
131,475
127,163
138,631
150,477
155,483
173,670
187,224
177,064
181,793
191,780
196,678
192,122
209,263
213,888
229,371
256,892
279,612
276,371
303,414
314,508
397,730
376,768
410,353
375,247
410,356
494,996
361,287
359,763
351,494
598,197
614,470
574,473
628,037
571,963
643,857
599,433
613,767
590,850
592,490
591,673
591,189
487,549
506,167
551,039
501,122
550,229
550,229501,122551,039506,167487,549591,189591,673592,490590,850613,767599,433643,857571,963628,037574,473614,470598,197351,494359,763361,287494,996410,356375,247410,353376,768397,730314,508303,414276,371279,612256,892229,371213,888209,263192,122196,678191,780181,793177,064187,224173,670155,483150,477138,631127,163131,475115,723116,254114,070100,06686,42787,93382,17080,14570,92264,82461,31364,57553,84655,50442,99544,286
       Other Current Assets 
1,008
2,526
2,420
4,938
3,756
3,223
3,755
4,986
8,810
7,084
8,607
23,092
44,572
25,267
42,150
60,931
72,386
14,149
18,785
22,615
15,876
6,108
10,742
15,060
25,271
7,516
8,684
8,669
7,742
8,793
8,144
10,804
31,240
12,303
111,225
15,564
59,489
76,013
194,719
84,719
100,376
19,406
161,177
129,486
198,610
29,224
28,155
23,092
29,230
19,749
18,405
23,204
21,203
21,531
40,217
46,209
39,672
45,016
66,868
50,605
590
2,350
2,35059050,60566,86845,01639,67246,20940,21721,53121,20323,20418,40519,74929,23023,09228,15529,224198,610129,486161,17719,406100,37684,719194,71976,01359,48915,564111,22512,30331,24010,8048,1448,7937,7428,6698,6847,51625,27115,06010,7426,10815,87622,61518,78514,14972,38660,93142,15025,26744,57223,0928,6077,0848,8104,9863,7553,2233,7564,9382,4202,5261,008
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,827,451
1,869,110
1,895,454
1,751,893
1,767,565
1,811,434
1,825,633
1,863,529
1,884,616
1,907,840
1,931,904
1,747,463
1,898,453
1,937,103
2,014,521
2,344,791
2,366,220
2,398,469
2,500,725
2,625,277
2,625,2772,500,7252,398,4692,366,2202,344,7912,014,5211,937,1031,898,4531,747,4631,931,9041,907,8401,884,6161,863,5291,825,6331,811,4341,767,5651,751,8931,895,4541,869,1101,827,451000000000000000000000000000000000000000000
       Property Plant Equipment 
109,981
109,659
97,315
111,472
96,317
114,791
95,522
136,626
105,037
124,617
105,006
154,223
136,898
180,435
165,452
183,437
166,796
256,658
245,012
264,760
260,707
295,923
279,606
278,884
278,092
351,848
349,734
367,676
356,821
441,632
450,373
485,807
483,566
499,438
499,604
496,551
490,004
525,344
523,904
522,366
574,330
616,765
617,553
621,254
626,218
717,252
715,275
745,215
749,017
766,656
782,435
772,898
763,868
881,342
915,294
959,367
1,009,495
1,175,693
1,192,194
1,198,999
1,282,634
1,433,549
1,433,5491,282,6341,198,9991,192,1941,175,6931,009,495959,367915,294881,342763,868772,898782,435766,656749,017745,215715,275717,252626,218621,254617,553616,765574,330522,366523,904525,344490,004496,551499,604499,438483,566485,807450,373441,632356,821367,676349,734351,848278,092278,884279,606295,923260,707264,760245,012256,658166,796183,437165,452180,435136,898154,223105,006124,617105,037136,62695,522114,79196,317111,47297,315109,659109,981
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,722
25,977
25,977
23,242
23,242
22,307
22,307
223,913
223,913
570,992
570,992
563,157
563,157
563,157
563,157
563,157
563,157
563,157
563,157
563,157
563,157
563,157
563,157
380,201
380,201
380,201
380,201
380,201
380,201
380,201
380,201
57,603
57,603
57,603
57,603
57,603
57,603
57,603
57,603
66,557
66,55757,60357,60357,60357,60357,60357,60357,60357,603380,201380,201380,201380,201380,201380,201380,201380,201563,157563,157563,157563,157563,157563,157563,157563,157563,157563,157563,157563,157570,992570,992223,913223,91322,30722,30723,24223,24225,97725,9771,7220000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
181,621
187,878
200,153
198,489
196,450
194,123
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000194,123196,450198,489200,153187,878181,621000000000000000000000000000000000000000
       Intangible Assets 
20,831
19,900
15,567
15,407
20,063
19,959
19,854
7,851
38,815
6,003
24,269
4,150
22,226
2,297
20,164
444
20,518
1,833
16,734
1,633
16,390
1,433
16,002
40,230
40,035
59,011
58,708
57,397
57,524
370,082
367,076
729,697
725,891
716,488
712,936
705,539
702,055
705,000
701,476
134,083
134,093
142,297
330,126
320,070
383,535
408,236
425,207
440,363
449,981
475,665
479,451
485,468
496,364
503,263
505,913
509,871
517,135
681,501
685,639
696,227
707,333
666,314
666,314707,333696,227685,639681,501517,135509,871505,913503,263496,364485,468479,451475,665449,981440,363425,207408,236383,535320,070330,126142,297134,093134,083701,476705,000702,055705,539712,936716,488725,891729,697367,076370,08257,52457,39758,70859,01140,03540,23016,0021,43316,3901,63316,7341,83320,51844420,1642,29722,2264,15024,2696,00338,8157,85119,85419,95920,06315,40715,56719,90020,831
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
48,113
53,846
59,127
19,901
20,620
22,608
776,915
9,091
8,272
40,505
60,165
40,020
63,608
44,526
66,389
22,623
23,791
21,773
28,470
8,986
8,98628,47021,77323,79122,62366,38944,52663,60840,02060,16540,5058,2729,091776,91522,60820,62019,90159,12753,84648,113000000000000000000000000000000000000000000
> Total Liabilities 
103,720
99,460
74,318
66,507
65,800
46,946
48,916
79,995
69,386
67,247
61,794
60,636
61,952
59,768
60,843
48,943
62,824
72,905
76,463
83,012
83,912
89,211
78,641
89,036
85,847
142,106
139,138
101,484
85,925
136,822
199,476
567,530
513,607
539,044
480,225
475,897
434,224
493,735
526,799
539,406
428,172
515,860
542,682
527,498
396,246
526,186
488,486
491,968
483,911
576,291
631,914
562,858
599,678
765,521
769,356
655,954
637,284
853,616
858,071
823,519
867,532
1,018,429
1,018,429867,532823,519858,071853,616637,284655,954769,356765,521599,678562,858631,914576,291483,911491,968488,486526,186396,246527,498542,682515,860428,172539,406526,799493,735434,224475,897480,225539,044513,607567,530199,476136,82285,925101,484139,138142,10685,84789,03678,64189,21183,91283,01276,46372,90562,82448,94360,84359,76861,95260,63661,79467,24769,38679,99548,91646,94665,80066,50774,31899,460103,720
   > Total Current Liabilities 
62,720
92,060
74,318
66,507
65,800
45,946
47,466
78,545
67,936
65,554
60,112
59,215
60,542
58,234
59,329
47,468
61,384
71,514
75,111
81,698
82,636
87,774
77,241
87,048
83,741
139,793
136,928
97,657
81,681
102,490
165,083
417,866
412,758
454,324
397,010
393,818
353,605
400,513
432,521
447,128
350,656
434,255
418,230
403,114
280,485
414,436
377,828
381,710
373,960
472,544
508,722
441,782
479,600
626,787
619,636
507,145
491,731
675,801
684,424
645,145
685,340
847,081
847,081685,340645,145684,424675,801491,731507,145619,636626,787479,600441,782508,722472,544373,960381,710377,828414,436280,485403,114418,230434,255350,656447,128432,521400,513353,605393,818397,010454,324412,758417,866165,083102,49081,68197,657136,928139,79383,74187,04877,24187,77482,63681,69875,11171,51461,38447,46859,32958,23460,54259,21560,11265,55467,93678,54547,46645,94665,80066,50774,31892,06062,720
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
50,945
50,945
20,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000020,00050,94550,945000000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
50,945
50,945
20,000
0
0
0
0
0
0
0
0
0
0
3,003
3,003
3,004
0
0
0
0
00003,0043,0033,003000000000020,00050,94550,945000000000000000000000000000000000000000000
       Accounts payable 
22,092
20,674
18,672
19,518
18,052
18,709
16,787
18,152
16,536
14,228
15,722
18,391
16,347
18,547
20,274
17,567
19,578
34,251
32,401
31,007
27,825
38,145
29,769
33,665
31,105
35,372
32,724
33,977
32,718
38,990
36,664
38,538
34,139
56,032
52,592
51,913
48,184
72,503
67,982
53,118
52,708
76,037
76,172
73,339
60,511
98,815
81,738
112,332
107,012
109,330
98,033
83,595
78,593
69,429
123,564
127,196
119,324
151,013
153,672
150,174
146,547
211,704
211,704146,547150,174153,672151,013119,324127,196123,56469,42978,59383,59598,033109,330107,012112,33281,73898,81560,51173,33976,17276,03752,70853,11867,98272,50348,18451,91352,59256,03234,13938,53836,66438,99032,71833,97732,72435,37231,10533,66529,76938,14527,82531,00732,40134,25119,57817,56720,27418,54716,34718,39115,72214,22816,53618,15216,78718,70918,05219,51818,67220,67422,092
       Other Current Liabilities 
21,116
24,386
28,596
26,139
30,748
27,237
30,679
47,393
40,700
43,626
36,690
36,124
39,495
35,987
39,055
29,901
41,806
37,263
42,710
50,691
54,811
49,629
47,472
53,383
46,636
104,420
104,204
63,680
48,964
63,500
128,420
369,327
368,619
388,292
344,418
341,906
305,420
328,010
364,539
265,748
254,539
165,166
282,885
161,222
196,404
130,547
253,749
112,621
263,920
148,754
350,950
131,060
343,690
247,300
409,491
127,017
296,366
396,751
389,506
302,538
2,034
2,316
2,3162,034302,538389,506396,751296,366127,017409,491247,300343,690131,060350,950148,754263,920112,621253,749130,547196,404161,222282,885165,166254,539265,748364,539328,010305,420341,906344,418388,292368,619369,327128,42063,50048,96463,680104,204104,42046,63653,38347,47249,62954,81150,69142,71037,26341,80629,90139,05535,98739,49536,12436,69043,62640,70047,39330,67927,23730,74826,13928,59624,38621,116
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
124,452
124,384
115,760
111,750
110,658
110,258
109,951
103,747
123,192
121,076
120,079
138,734
149,720
148,809
145,553
177,814
173,647
178,374
182,192
171,348
171,348182,192178,374173,647177,814145,553148,809149,720138,734120,079121,076123,192103,747109,951110,258110,658111,750115,760124,384124,452000000000000000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-50,945
-50,945
-20,000
0
0
0
0
0
19,731
19,651
19,868
23,743
22,960
22,083
21,068
24,063
22,283
27,180
31,918
47,817
47,81731,91827,18022,28324,06321,06822,08322,96023,74319,86819,65119,73100000-20,000-50,945-50,945000000000000000000000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
40,000
40,000
28,000
14,028
14,028
14,028
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000014,02814,02814,02828,00040,00040,000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
119,880
141,188
173,179
198,799
235,886
253,837
286,204
307,818
325,100
337,756
367,141
374,387
383,076
375,493
386,181
391,598
400,567
411,501
413,280
423,114
430,805
0
0
00430,805423,114413,280411,501400,567391,598386,181375,493383,076374,387367,141337,756325,100307,818286,204253,837235,886198,799173,179141,188119,880000000000000000000000000000000000000000
> Total Stockholder Equity
110,524
125,879
148,644
150,630
486,714
495,410
503,520
491,399
506,891
519,593
524,677
510,154
526,001
543,884
550,477
534,749
557,694
580,029
593,588
597,599
629,624
660,599
680,109
660,134
701,412
738,897
719,531
775,484
825,729
1,216,940
1,191,603
1,230,357
1,296,376
1,358,986
1,410,572
1,406,152
1,576,482
1,677,858
1,739,520
1,705,321
1,900,609
1,920,326
2,650,145
2,573,354
2,764,283
2,626,678
2,708,070
2,630,708
2,775,205
2,835,740
2,956,577
2,799,796
2,985,171
2,786,597
3,011,622
2,854,908
3,044,930
3,208,623
3,419,565
3,240,265
3,522,940
3,737,400
3,737,4003,522,9403,240,2653,419,5653,208,6233,044,9302,854,9083,011,6222,786,5972,985,1712,799,7962,956,5772,835,7402,775,2052,630,7082,708,0702,626,6782,764,2832,573,3542,650,1451,920,3261,900,6091,705,3211,739,5201,677,8581,576,4821,406,1521,410,5721,358,9861,296,3761,230,3571,191,6031,216,940825,729775,484719,531738,897701,412660,134680,109660,599629,624597,599593,588580,029557,694534,749550,477543,884526,001510,154524,677519,593506,891491,399503,520495,410486,714150,630148,644125,879110,524
   Common Stock
60,000
60,000
63,000
63,000
84,000
84,000
84,000
151,200
151,200
151,200
151,200
189,000
189,000
189,000
189,000
189,000
189,000
189,000
189,000
241,145
241,145
241,966
241,966
290,359
290,359
290,359
377,467
377,379
377,379
407,864
530,223
530,129
547,601
547,601
547,601
711,882
712,523
712,481
712,481
997,474
997,474
997,366
1,050,320
1,050,320
1,050,320
1,050,298
1,050,298
1,365,388
1,365,388
1,365,388
1,365,388
1,638,466
1,638,466
1,638,466
1,638,466
1,638,466
1,638,466
1,673,258
1,673,258
1,673,258
0
0
001,673,2581,673,2581,673,2581,638,4661,638,4661,638,4661,638,4661,638,4661,638,4661,365,3881,365,3881,365,3881,365,3881,050,2981,050,2981,050,3201,050,3201,050,320997,366997,474997,474712,481712,481712,523711,882547,601547,601547,601530,129530,223407,864377,379377,379377,467290,359290,359290,359241,966241,966241,145241,145189,000189,000189,000189,000189,000189,000189,000189,000151,200151,200151,200151,20084,00084,00084,00063,00063,00060,00060,000
   Retained Earnings 
15,128
23,462
39,546
41,531
56,521
61,660
69,771
56,049
71,542
80,109
85,192
70,669
88,253
100,313
106,906
91,179
114,123
131,241
144,801
119,120
148,912
167,810
235,338
213,545
251,342
279,105
258,866
296,718
344,470
371,806
345,828
395,738
452,013
507,929
555,119
541,527
618,547
703,531
763,079
726,766
827,788
859,381
800,894
724,217
833,929
826,299
907,690
831,127
967,806
1,027,709
1,153,294
998,634
1,184,009
961,261
1,134,159
978,162
1,228,010
1,337,042
1,522,660
1,316,093
1,281,324
1,397,770
1,397,7701,281,3241,316,0931,522,6601,337,0421,228,010978,1621,134,159961,2611,184,009998,6341,153,2941,027,709967,806831,127907,690826,299833,929724,217800,894859,381827,788726,766763,079703,531618,547541,527555,119507,929452,013395,738345,828371,806344,470296,718258,866279,105251,342213,545235,338167,810148,912119,120144,801131,241114,12391,179106,906100,31388,25370,66985,19280,10971,54256,04969,77161,66056,52141,53139,54623,46215,128
   Capital Surplus 00000000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000-71,073-152,921-152,921-152,921-153,334-228,184-228,184-228,184-228,18400000000000000000000000000000000
   Other Stockholders Equity 00000000000000000000000000000000000000000000000000000000000000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue2,865,752
Cost of Revenue-620,344
Gross Profit2,245,4082,245,408
 
Operating Income (+$)
Gross Profit2,245,408
Operating Expense-1,899,693
Operating Income966,059345,715
 
Operating Expense (+$)
Research Development254,680
Selling General Administrative898,609
Selling And Marketing Expenses0
Operating Expense1,899,6931,153,289
 
Net Interest Income (+$)
Interest Income5,894
Interest Expense-1,874
Other Finance Cost-1,067
Net Interest Income2,953
 
Pretax Income (+$)
Operating Income966,059
Net Interest Income2,953
Other Non-Operating Income Expenses0
Income Before Tax (EBT)919,930966,059
EBIT - interestExpense = -1,874
847,229
849,103
Interest Expense1,874
Earnings Before Interest and Taxes (EBIT)0921,803
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax919,930
Tax Provision-61,341
Net Income From Continuing Ops858,589858,589
Net Income847,229
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-2,953
 

Technical Analysis of Anhui Anke BioTech Group
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Anhui Anke BioTech Group. The general trend of Anhui Anke BioTech Group is BEARISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Anhui Anke BioTech Group's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-28.6%) Bearish trend (28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Anhui Anke BioTech Group.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 10.09 < 10.24 < 10.47.

The bearish price targets are: 7.56 > 7.0088949677419.

Tweet this
Anhui Anke BioTech Group Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Anhui Anke BioTech Group. The current mas is .

The long score for the Moving Averages is 5/14.
The longshort score for the Moving Averages is -4/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Anhui Anke BioTech Group Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Anhui Anke BioTech Group. The current macd is -0.02676607.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Anhui Anke BioTech Group price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Anhui Anke BioTech Group. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Anhui Anke BioTech Group price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Anhui Anke BioTech Group Daily Moving Average Convergence/Divergence (MACD) ChartAnhui Anke BioTech Group Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Anhui Anke BioTech Group. The current adx is 13.32.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Anhui Anke BioTech Group shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Anhui Anke BioTech Group Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Anhui Anke BioTech Group. The current sar is 8.86.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Anhui Anke BioTech Group Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Anhui Anke BioTech Group. The current rsi is 52.75. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Anhui Anke BioTech Group Daily Relative Strength Index (RSI) ChartAnhui Anke BioTech Group Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Anhui Anke BioTech Group. The current phase is Overbought in bear market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Anhui Anke BioTech Group price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Anhui Anke BioTech Group Daily Stochastic Oscillator ChartAnhui Anke BioTech Group Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Anhui Anke BioTech Group. The current cci is 27.10.

Anhui Anke BioTech Group Daily Commodity Channel Index (CCI) ChartAnhui Anke BioTech Group Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Anhui Anke BioTech Group. The current cmo is 8.68406606.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Anhui Anke BioTech Group Daily Chande Momentum Oscillator (CMO) ChartAnhui Anke BioTech Group Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Anhui Anke BioTech Group. The current willr is -12.38938053.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Anhui Anke BioTech Group Daily Williams %R ChartAnhui Anke BioTech Group Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Anhui Anke BioTech Group.

Anhui Anke BioTech Group Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Anhui Anke BioTech Group. The current atr is 0.30811806.

Anhui Anke BioTech Group Daily Average True Range (ATR) ChartAnhui Anke BioTech Group Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Anhui Anke BioTech Group. The current obv is 402,190,076.

Anhui Anke BioTech Group Daily On-Balance Volume (OBV) ChartAnhui Anke BioTech Group Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Anhui Anke BioTech Group. The current mfi is 51.16.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Anhui Anke BioTech Group Daily Money Flow Index (MFI) ChartAnhui Anke BioTech Group Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Anhui Anke BioTech Group.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-21BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-25STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside

6.3. Candlestick Patterns

Anhui Anke BioTech Group Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Anhui Anke BioTech Group based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.750
Ma 20Greater thanMa 509.727
Ma 50Greater thanMa 1009.777
Ma 100Greater thanMa 2009.800
OpenGreater thanClose9.540
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Anhui Anke BioTech Group with someone you think should read this too:
  • Are you bullish or bearish on Anhui Anke BioTech Group? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Anhui Anke BioTech Group? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Anhui Anke BioTech Group

I send you an email if I find something interesting about Anhui Anke BioTech Group.


Comments

How you think about this?

Leave a comment

Stay informed about Anhui Anke BioTech Group.

Receive notifications about Anhui Anke BioTech Group in your mailbox!